AHVAP joins FDA TAP Pilot as non-FDA participant

The Association of Healthcare Value Analysis Professionals has been welcomed into the FDA’s Total Product Life Cycle Advisory Program Pilot as a non-FDA party. The move gives AHVAP a role in earlier device-development conversations that could shape clinical adoption, coverage and patient access.

Why it matters: - AHVAP’s participation puts healthcare value analysis into the FDA’s device-development pipeline earlier. - The role could help innovators better understand what hospitals and health systems need before a product reaches the market. - Earlier alignment may speed evidence-based adoption of medical devices that matter to patients and providers.

What happened: - AHVAP said Tuesday it has been welcomed as a participating non-FDA party in the FDA’s Total Product Life Cycle Advisory Program Pilot, or TAP Pilot. - The pilot is administered by the Center for Devices and Radiological Health. - AHVAP’s participation is voluntary. - AHVAP said engagements with TAP Innovators will be conducted independently. - AHVAP said its involvement does not constitute an endorsement of any specific device or company.

The details: - The TAP Pilot is designed to give medical device developers earlier and more frequent interactions with CDRH. - The program also expands strategic engagement with non-FDA parties such as professional associations, clinicians and payers. - FDA’s goal is to support faster development and broader patient access to safe, effective, high-quality medical devices of public health importance. - TAP Innovators may request early engagement with non-FDA parties like AHVAP. - FDA anticipates those discussions may cover clinical adoption, professional guidelines, publication, coding, coverage and payment, and outcomes that matter to patients and healthcare providers. - AHVAP members evaluate new products for clinical evidence, safety, cost and operational impact before those products reach the bedside. - AHVAP said that by participating in TAP, the organization can help innovators understand what health systems need to see earlier in development.

Between the lines: - The partnership reflects a broader shift toward involving value analysis professionals before launch, not just after regulatory clearance. - For device makers, that could reduce friction later with hospital committees, coverage decisions and implementation. - For AHVAP, the TAP role elevates value analysis as part of healthcare innovation, not only procurement. - Dr. Hudson Garrett Jr., AHVAP’s executive director and executive vice president, said the program gives the profession a meaningful voice in shaping how new technologies are evaluated and adopted. - Garrett said the biggest impact comes during design and development, before a product reaches the market.

What's next: - TAP Innovators can begin requesting early engagement with AHVAP through the pilot. - AHVAP will likely use those interactions to inform innovators on evidence needs, adoption barriers and real-world implementation considerations. - The organization said it aims to help get safe, effective, high-value technologies to patients sooner.

The bottom line: - AHVAP’s entry into the FDA TAP Pilot formalizes a new channel between device innovators and the healthcare professionals who help decide whether products get used in hospitals.